Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





n-BUTYL GLYCIDYL								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 2426-08-6; **Chemical Formula:** C4H9OCH2CH2OH
The former OSHA limit for n-butyl glycidyl ether was 50 ppm as an 8-hour TWA. The ACGIH-recommended TLV is 25 ppm; NIOSH has recommended that occupational exposure to n-butyl glycidyl ether not exceed 5.6 ppm as a 15-minute short-term level. The proposed PEL was 25 ppm as an 8-hour TWA, and the final rule promulgates this limit. n-Butyl glycidyl ether is a clear, colorless liquid.
OSHA’s former PEL of 50 ppm, which was adopted from the ACGIH’s 1968 TLV list, was based on a Dow Chemical Company report (cited in ACGIH 1986/Ex. 1-3) that showed that repeated applications of n-butyl glycidyl ether to the skin of humans caused irritation and sensitization; at the time, the ACGIH concluded that a limit of 50 ppm would prevent these irritant responses. Subsequently, the ACGIH reduced the TLV to 25 ppm, noting that the 50-ppm limit was only 13 times lower than the 8-hour LC(50) (670 ppm) reported for this chemical in rats, and that a wider margin of protection was desirable.
The NIOSH limit of 5.6 ppm was recommended in the Institute’s June 1978 criteria document on glycidyl ethers (NIOSH 1978d/Ex. 1-232). This limit was based, in large part, on mutagenic studies conducted in microbial and mammalian test systems, as well as on some evidence for other members of the glycidyl ether family showing that exposure is associated with testicular atrophy and hematopoietic abnormalities in laboratory animals. After publication of its Criteria Document, NIOSH received a confidential report prepared for the Shell Development Company by Anderson et al. (1957, as cited in ACGIH 1986/Ex. 1-3, p. 81), who had conducted a rat inhalation study. In this research, rats were exposed to 38 ppm, 75 ppm, 150 ppm, or 300 ppm n-butyl glycidyl ether for seven hours daily, five days per week for 10 weeks. Atrophic testes were found in 5 of 10 rats exposed to 300 ppm, very small testes were found in 1 of 10 rats exposed to 150 ppm, and patchy atrophy was found in the testes of 1 of 10 rats exposed to 75 ppm. No effects were observed in rats exposed at 38 ppm. Based on this additional evidence, NIOSH reaffirmed its REL for n-butyl glycidyl ether in a current intelligence bulletin (NIOSH 1978p, as cited in ACGIH 1986/Ex. 1-3, p. 81).
The Workers Institute for Safety and Health (WISH) and the AFL-CIO submitted posthearing comments on butyl glycidyl ether (Exs. 116, 194). These commenters opposed OSHA’s proposal to adopt the ACGIH TLV for this substance on the basis of the reproductive study published in a NIOSH CIB (discussed above) which shows testicular atrophy in exposed laboratory animals. According to WISH:
OSHA’s review of this substance in the proposal attempts to state that the 25 ppm ACGIH level is protective against these reproductive effects because a no-effect level of 38 ppm was observed (Ex. 116).WISH found this conclusion unjustifiable because of the short exposure period (10 weeks) used in the study establishing the NOEL for reproductive effects and because considerable uncertainty always surrounds no-effect-level studies. In addition, WISH pointed out that “fertility in rats is less sensitive to certain testicular effects than human fertility” and, therefore, that this animal is not the best predictor of human reproductive effects (Ex. 116). In response to these comments, OSHA wishes to clarify that the Agency did not intend to imply in the proposal that the 25-ppm limit would protect against all risk of possible reproductive effects. In fact, the proposal merely noted that 25 ppm was below the no-effect level for reproductive effects in rats. The Agency agrees with WISH that the use of a longer exposure period in the Anderson et al. (1957, as cited in ACGIH 1986/Ex. 1-3, p. 81) reproductive study might have established a lower NOEL.
However, based on the existing evidence for reproductive effects linked to n-butyl glycidyl ether exposure, OSHA concludes that reducing the PEL from 50 ppm to 25 ppm will substantially reduce the significant risk of these reproductive effects and will also protect workers against the irritation and sensitization effects, all of which constitute material health impairment caused by exposure to this chemical. The Agency notes that NIOSH’s REL of 5.6 ppm (15-minute STEL) is based on the result of in vitro testing in both microbial and mammalian systems; extensive extrapolation is required to predict effects in humans on these bases. The final rule establishes a permissible exposure limit of 25 ppm TWA for n-butyl glycidyl ether.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue